Oxygenation strategies during flexible bronchoscopy: a review of the literature

Corrado Pelaia1, Andrea Bruni2, Eugenio Garofalo2, Serena Rovida3, Eugenio Arrighi1, Gianmaria Cammarota4, Paolo Navalesi5, Girolamo Pelaia1 and Federico Longhini2*

Abstract
During flexible fiberoptic bronchoscopy (FOB) the arterial partial pressure of oxygen can drop, increasing the risk for respiratory failure. To avoid desaturation episodes during the procedure several oxygenation strategies have been proposed, including conventional oxygen therapy (COT), high flow nasal cannula (HFNC), continuous positive airway pressure (CPAP) and non-invasive ventilation (NIV). By a review of the current literature, we merely describe the clinical practice of oxygen therapies during FOB. We also conducted a pooled data analysis with respect to oxygenation outcomes, comparing HFNC with COT and NIV, separately. COT showed its benefits in patients undergoing FOB for broncho-alveolar lavage (BAL) or brushing for cytology, in those with peripheral arterial oxyhemoglobin saturation < 93% prior to the procedure or affected by obstructive disorder. HFNC is preferable over COT in patients with mild to moderate acute respiratory failure (ARF) undergoing FOB, by improving oxygen saturation and decreasing the episodes of desaturation. On the opposite, CPAP and NIV guarantee improved oxygenation outcomes as compared to HFNC, and they should be preferred in patients with more severe hypoxemic ARF during FOB.

Keywords: Bronchoscopy, Oxygen, High flow nasal cannula, Continuous positive airway pressure, Non-invasive ventilation

Introduction
Flexible fiberoptic bronchoscopy (FOB) is a diagnostic and sometimes therapeutic procedure, commonly performed in patients affected by airway or lung parenchyma disorders. FOB has several applications, including plug removal in presence of abundant secretions or ineffective cough, bronchoalveolar lavage (BAL), biopsy, or endoscopic management of bleeding.

The majority of patients undergoing FOB suffer from conditions that impair gas exchange such as pneumonia, interstitial lung diseases, as well as lung and bronchial neoplasms. During the procedure arterial partial pressure of oxygen can drop even more than 10–20 mmHg, with an increased risk for respiratory failure [1, 2]. In order to avoid desaturation episodes, oxygen support provided by conventional therapy or non-invasive ventilation is usually required during and after FOB.

Through a review of the literature, we discuss the rationale and all the alternative oxygenation strategies adopted during FOB. In addition, in the attempt to provide some clinical evidences, we have also conducted a quantitative synthesis of findings comparing high flow oxygen through nasal cannula (HFNC) with conventional oxygen therapy (COT) and non-invasive ventilation (NIV), separately, with respect to the lowest saturation during procedures and the number of episodes of desaturation.
Evidence acquisition
This review was conducted in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement. The review protocol has been registered in Prospero (CRD42020153343).

Study selection and inclusion criteria
All cited articles include adult patients, receiving one or more modalities of oxygen support administered during flexible bronchoscopy for any reason (diagnostic or interventional), without restrictions related to the type of bronchoscopy procedure and to the anesthetic risk.

We included all randomized, quasi-randomized, prospective and retrospective studies, published in indexed scientific journals from inception to May 1st, 2021. We excluded papers published in languages other than English, Italian, French or Spanish as well as case reports or series, review, systematic reviews or meta-analysis and studies published in abstract form. Papers including patients undergoing rigid bronchoscopy were also excluded. References of included papers, reviews, systematic reviews and meta-analysis were also examined to identify potential studies of interest missed during the primary search.

All oxygen therapy modalities utilized during flexible bronchoscopy were evaluated. Specifically, we considered: (1) COT, consisting of low oxygen flow administration through nasal prongs, oxygen mask with or without reservoir, and Venturi mask [3]; (2) HFNC, consisting of administration of high flows (up to 60 L/min) of air/oxygen admixtures, heated (at temperatures ranging from 31 to 37 °C) and fully humidified (up to 44 mg H₂O/L) [4], providing an inspired oxygen fraction ranging from 21 to 100%; (3) continuous positive airway pressure (CPAP), based on the application of a positive end-expiratory pressure (PEEP) throughout the whole respiratory cycle by means of interfaces such as mask or helmet [5, 6], and (4) NIV, based on the application of a PEEP by means of a mask or helmet, with an inspiratory pressure support triggered by the patient and delivered by a ventilator [7, 8].

Search strategy
Two authors (A.B. and C.P.) independently searched MEDLINE, EMBASE, and Scopus Database of Systematic Reviews using the following keywords and their related MeSH terms: "bronchoscopy", "conventional oxygen therapy", "continuous positive airway pressure", "bilevel continuous positive airway pressure", "airway pressure release ventilation", "noninvasive ventilation", and "high flow nasal oxygen". The search strategy is detailed in the Electronic Supplemental Material (ESM). Controlled vocabulary terms, text words, and keywords were variably combined. Blocks of terms per concept were created. These authors also independently checked all the articles, and selected those enrolling adult patients undergoing bronchoscopy which required oxygen therapy or other modalities of respiratory support. In case of disagreement, the opinion of a third examiner (F.L.) was requested for a conclusive decision.

Definition of clinical outcomes
A quantitative synthesis of findings has been conducted for the lowest saturation during procedures and the number of episodes of desaturation. The lowest saturation was defined as the lowest value reported by the included studies of the arterial (SaO₂) or peripheral (SpO₂) oxygen saturation during the FOB procedure. The number of episodes of desaturation was intended as the number of patients with one or more episodes of desaturations during the procedure, as defined by SaO₂ or SpO₂ < 90% for a minimum time defined by every single study.

Statistical analysis
Dichotomous outcomes are presented as risk ratios (RR) with 95% confidence intervals (CIs). For normally distributed continuous data, we have calculated the mean difference (MD) with corresponding 95% CIs. We use medians and interquartile ranges for continuous data that were not normally distributed. Meta-analyses have been performed using random-effects models. We have assessed heterogeneity by visually inspecting the forest plots to determine closeness of point estimates with each other and overlap of CIs. We used the $\chi^2$ test with a P value of 0.10 to indicate statistical significance, and the I² statistic to measure heterogeneity. We have also considered the magnitude and direction of effects, and the strength of evidence for heterogeneity (e.g. P value from the $\chi^2$ test), when determining the importance of the observed I² value. P values < 0.05 were considered statistically significant.

Results
The electronic search identified 5157 potentially relevant studies. Detailed description of the selection process flow is provided in Fig. 1. We selected 32 full-text manuscripts (Table 1), referring to 3 multi-centered and 29 single-centered studies, respectively [1, 9–39]. With the exception of 7 studies, all trials were performed in University Hospitals. Among all studies, 18 were conducted in European countries. Overall, the 32 selected studies enrolled 2517 patients with a median of 40 [12–60] patients per study, and a median patient age of 60 [53–64] years.
Different forms of oxygen therapies and ventilatory support: the choice rationale
Alteration of respiratory mechanics during FOB occurs physiologically. In non-intubated patients, the fiberscope occupies about 10% of the cross-sectional area of the trachea, and 15% of the cricoid ring. As a consequence, in patient’s airways an increase in air flow resistance develops, and the work of breathing thus enhances [40]. When suction is applied, end-expiratory lung volume is reduced, leading to alveolar de-recruitment, increased shunt and venous admixture [40–42]. As mentioned, these respiratory changes revert after FOB, but their reversal may take from 15 min up to several hours in severe parenchymal lung diseases [40].

In addition, FOB indirectly causes also significant haemodynamic changes. The increase of airway resistance and work of breathing theoretically leads to changes in intra-thoracic pressure, that may also affect venous return and afterload, while reducing cardiac output. However, it has been reported that cardiac output increases by 50% secondary to sympathetic stimulation during FOB, and it returns to baseline in 15 min after its completion [40, 43, 44]. In fragile or cardiopathic patients, FOB may cause a dangerous cardiopulmonary distress, associated with electrocardiographic alteration in up to 21% of awake patients over 60 years old [44]. This aspect should also drive the clinician to choose the more appropriate oxygenation strategy from a physiological point of view.

COT through nasal prongs is appropriate to reduce transitory hypoxemia [42]. However, the inspired oxygen fraction (FiO₂) cannot be predicted, and might not be enough in severe cases.

When lung parenchyma is already compromised by an underlying pathologic condition, uncomplicated FOB may worsen gas exchange, leading to development of respiratory failure [1, 2, 41, 45]. HFNC has been introduced in clinical practice as a valuable alternative for oxygen support during FOB [4, 46–48]. Four main reasons support its use during and after the procedure: (1) the flow up to 60 L/min ensures a more stable FiO₂, as it is able to match the increased patient’s inspiratory flow [49]; (2) the high flow generates a small positive expiratory airway pressure depending on the flow rate, the upper airway anatomy, the breathing through the nose or mouth, and the size of the cannula in relation to the nostrils [49]; (3) the high flow reduces the dead space in the upper airways up to 70 ml, and increases the alveolar ventilation
### Table 1 Characteristics of the studies included in the systematic review

| Year             | Patients enrolled | FOB performed | Study type     | Clinical status | Setting            | RS before FOB | RS during FOB | FOB purpose | Analgosedation strategy | Main outcomes                                                                 |
|------------------|-------------------|---------------|----------------|----------------|--------------------|---------------|---------------|--------------|-------------------------|--------------------------------------------------------------------------------|
| Antonelli M., et al. [1] | 1996   | 8              | 8              | Interventional | Acute              | ICU           | COT           | Diagnostic   | Lidocaine              | O₂ saturation, PaO₂/FiO₂, PaCO₂, RR, HR, intubation, mortality                   |
| Jones A.M., et al. [9] | 2000   | 1074           | 2261           | Observational  | Chronic            | Ward          | None          | COT          | Diagnostic              | Midazolam, lidocaine                                                        |
| Onakpoya U.U., et al. [10] | 2012  | 61             | 67             | Observational  | Chronic            | Ward          | None          | COT          | Diagnostic              | O₂ saturation                                                                |
| Golpe R., Mateos A. [11] | 2002  | 44             | 44             | Observational  | ND                 | ND            | None          | COT          | ND                      | O₂ saturation                                                                |
| Aljanpour E., et al. [12] | 2010  | 146            | 146            | Observational  | ND                 | ND            | None          | COT          | ND                      | O₂ saturation                                                                |
| Crocco C., et al. [13] | 2013   | 169            | 181            | Observational  | Acute              | ICU           | COT, NPPV     | COT, NPPV    | Diagnostic, therapeutic | ND                                                                            |
| Ghio A.J., et al. [14] | 2007   | 12             | 12             | Prospective randomized | Healthy volunteers | Outpatients | COT or none | COT or none | Research               | Lidocaine                                                                    |
| McCain T.W., et al. [15] | 2001   | 97             | 97             | Prospective randomized | Chronic          | ND            | COT          | Diagnostic   | Lidocaine              | O₂ saturation, O₂ flow rate                                                |
| Miyagi K., et al. [16] | 2014   | 5              | 5              | Observational  | Acute              | ICU           | COT          | HFNC         | Diagnostic   | ND                      | O₂ saturation                                                                |
| La Combe B., et al. [17] | 2016   | 30             | 30             | Observational  | Acute              | ICU           | COT          | HFNC         | Diagnostic   | ND                      | O₂ saturation, dyspnea, intubation, mortality                                |
| Longhini F., et al. [18] | 2021   | 36             | 36             | Prospective randomized | Chronic          | Outpatients | None          | COT or HFNC | Diagnostic   | Lidocaine              | O₂ saturation, PaO₂, ΔEEL, DD, TF                                           |
| Chung S.M., et al. [19] | 2018   | 10             | 10             | Observational  | Acute, chronic     | Ward          | COT          | HFNC         | Diagnostic, therapeutic | Midazolam, propofol, lidocaine                                              |
| Service J.A., et al. [20] | 2018   | 182            | 182            | Observational  | Chronic            | Outpatients | None          | HFNC         | Diagnostic   | Remifentanil, propofol or midazolam                                         |
| Ben-Menachem E., et al. [21] | 2020  | 76             | 76             | Prospective randomized | Chronic          | Ward          | None          | COT or HFNC | Diagnostic   | ND                      | O₂ saturation                                                                |
| Lucangelo U., et al. [22] | 2012   | 45             | 45             | Prospective randomized | Acute, chronic   | Ward          | None          | COT or HFNC | Diagnostic   | Midazolam, lidocaine, O₂ saturation, PaO₂/FiO₂                              |
| Irfan M., et al. [23] | 2021   | 40             | 40             | Prospective randomized | Chronic          | Ward          | None          | COT or HFNC | Diagnostic   | ND                      | O₂ saturation                                                                |
| Year | Patients enrolled | FOB performed | Study type | Clinical status | Setting | RS before FOB | RS during FOB | FOB purpose | Analgesedation strategy | Main outcomes |
|------|-------------------|---------------|------------|----------------|---------|---------------|---------------|-------------|---------------------|---------------|
| 2018 | 60                | 60            | Prospective randomized | Chronic | ND     | None          | COT or HFNC   | Diagnostic | Midazolam, opioids and/or propofol, lidocaine | O₂ saturation |
| 2018 | 32                | 33            | Observational         | Acute   | Ward  | COT or HFNC   | HFNC          | Diagnostic | Midazolam, lidocaine | O₂ saturation, PaO₂/FiO₂ |
| 2000 | 30                | 30            | Prospective randomized | Acute   | Ward, ICU | COT          | COT or CPAP  | Diagnostic | Lidocaine | O₂ saturation, PaO₂, ventilatory assistance requirement |
| 2002 | 26                | 26            | Prospective randomized | Acute   | ICU   | COT           | COT or NPPV   | Diagnostic | Lidocaine | PaO₂/FiO₂, HR, MAP, intubation |
| 2011 | 40                | 40            | Observational         | Acute   | ICU   | NIV           | NIV           | Diagnostic, therapeutic | Midazolam, propofol, lidocaine | PaO₂/FiO₂, intubation |
| 2016 | 28                | 28            | Observational         | Acute   | ICU   | NIV           | NIV           | Diagnostic, therapeutic | Midazolam, lidocaine | PaO₂/FiO₂, intubation |
| 2010 | 35                | 35            | Observational         | Acute   | Ward, ICU | NIPPV        | NIPPV         | Diagnostic, therapeutic | Lidocaine | O₂ saturation, RR, HR, intubation, mortality |
| 2010 | 12                | 12            | Observational         | Acute   | ICU   | COT           | NPPV          | Diagnostic | Xylocaine | O₂ saturation, PaO₂/FiO₂, intubation |
| 2003 | 4                 | 4             | Interventional        | Acute   | ICU   | COT           | NPPV          | Diagnostic | Lidocaine | O₂ saturation, PaO₂/FiO₂, PaCO₂, RR, HR, MAP, intubation |
| 2012 | 6                 | 6             | Observational         | Acute   | Ward  | COT           | NIV           | Diagnostic, therapeutic | Lidocaine | O₂ saturation, PaO₂/FiO₂, intubation |
| 2020 | 29                | 29            | Retrospective         | Acute   | Ward  | COT           | NIV, CMV      | Therapeutic | Dezocine, midazolam, lidocaine | O₂ saturation, PaO₂, HR, SBP, type of procedures, success rate, procedure time |
| 2000 | 10                | 10            | Prospective randomized | Acute   | ICU   | None          | NIPPV         | Diagnostic | Lidocaine | O₂ saturation, PaO₂, PaCO₂, intubation, mortality |
| Year | Patients enrolled | FOB performed | Study type | Clinical status | Setting | RS before FOB | RS during FOB | FOB purpose | Analgosedation strategy | Main outcomes |
|------|------------------|---------------|------------|----------------|---------|---------------|---------------|-------------|-------------------------|---------------|
| 2018 | 40               | 20            | Prospective randomized | Acute | Ward | NIV | NIV | Therapeutic | Midazolam, lidocaine | O₂ saturation |
| 2010 | 30               | 30            | Prospective | Acute | RICU, ICU | NPPV | NPPV, CMV | Diagnostic | Lidocaine | O₂ saturation, PaO₂/FiO₂, PaCO₂, pH |
| 2014 | 40               | 40            | Prospective randomized | Acute | ICU | COT | NIV or HFNC | Diagnostic, therapeutic | Propofol, lidocaine | O₂ saturation, PaO₂/FiO₂, PaCO₂, HR, MAP, procedure time, intubation, mortality |
| 2019 | 51               | 51            | Prospective randomized | Acute | Ward or RICU | NIV or HFNC | NIV or HFNC | Diagnostic | Fentanyl, lidocaine | O₂ saturation, PaO₂, PaCO₂, pH, RR, HR, MAP, dyspnea |

ND not defined, FOB flexible fiberoptic bronchoscopy, RS respiratory support, ICU intensive care unit, RICU respiratory intermediate care unit, NIV noninvasive ventilation, COT conventional oxygen therapy, CPAP continuous positive airway pressure, HFNC high flow oxygen through nasal cannula, CMV conventional mechanical ventilation, PaO₂ arterial partial pressure of oxygen, FiO₂ fraction of inspired oxygen, PaCO₂ arterial partial pressure of carbon dioxide, RR respiratory rate, HR heart rate, ΔEELI changes of end-expiratory lung impedance, DD diaphragm displacement, TF thickening fraction, MAP mean arterial pressure, SBP systolic blood pressure
and (4) the HFNC decreases the resistive breathing effort, reducing the upper airway resistance [49].

The application of CPAP has also been adopted during FOB. CPAP releases a positive pressure throughout the entire breathing cycle, thereby recruiting lung atelectatic regions [50], reducing venous admixture [51], and decreasing the patient’s inspiratory effort [5].

The use of NIV can also ameliorate gas exchange, thus diminishing the respiratory effort. However, despite these benefits NIV is negatively affected by poor patient-ventilator interaction, which impairs its effectiveness [7, 8, 52–54].

COT during FOB
The use of COT during FOB has been investigated in several studies. Although not always required [9], COT showed its benefits in patients with higher risk of desaturation, including those with baseline (before procedure) peripheral arterial oxyhemoglobin saturation (SpO2) < 93% [10], an obstructive ventilatory defect [11], or a forced expiratory volume in the first second (FEV1) lower than 1 L [9, 12]. COT is also indicated in those patients suffering from chronic obstructive pulmonary disease and immunosuppression, due to their higher risk of intubation in the 24 h following FOB [13].

When FOB is carried out for BAL [14] or brushing performed for cytological examination [10], COT is needed as well. Oxygen can be delivered by a cannula placed either in the nose or in the mouth, as the average SpO2 within the procedure is similar between the two modalities, and no sinus symptoms or nasal congestion have been reported [15].

HFNC during FOB
HFNC consists of a mixture of air and oxygen, delivered through a maximally heated and humidified flow up to 60 L/min.

HFNC has been successfully used to prevent acute respiratory failure (ARF) from worsening during FOB. A small study conducted on 5 patients found that oxygenation was well maintained for 30 min after FOB for BAL, and only one patient required non-invasive positive pressure ventilation 16 h after FOB [16]. Similar results were reported in regard to a larger observational trial, with 30 critically ill patients affected by ARF during nasal FOB performed with non-open mouth [17] and 60 patients requiring FOB for BAL [18]. Improvement of post-FOB SpO2 was also described, as well as prevention of mucosal injury and patient discomfort, thanks to the humidified and heated gas flow [19]. In a prospective study carried out using HFNC during FOB for endobronchial ultrasound (EBUS) with deep sedation, no difference in desaturation events was detected between procedures lasting less or more than 40 min [20]. In several studies, HFNC has also been compared with other oxygen support modalities, as shown below. In a randomized controlled trial on post-lung transplant patients undergoing FOB for transbronchial lung biopsy, the procedure was interrupted when low-flow nasal oxygen was applied, whereas no similar episodes occurred with HFNC [21]. When compared to Venturi mask, HFNC at 60 L/min provided better oxygenation outcomes, whereas no difference was observed between HFNC 40 L/min and Venturi mask 40 L/min [22]. A very recent randomized controlled trial showed that the use of HFNC instead of COT, during FOB for EBUS, was associated with a statistically significant lower drop in SpO2 [23].

When compared with COT in patients without ARF undergoing EBUS with conscious sedation, HFNC did not significantly reduce the rate of in-traprocedural desaturation episodes [24]. During FOB for BAL, effectiveness and safety of HFNC versus COT was tested in patients with ARF [25]. No relevant events, such as endotracheal intubation, were reported within the 24 h following FOB for BAL. No statistically significant differences between patients undergoing or not HFNC with regard to transient hypoxemia, fever, hypotensive events, and endotracheal intubation rate were observed [25].

CPAP during FOB
The use of CPAP through full-face mask during FOB has been investigated in patients with hypoxic ARF (PaO2/FiO2 <300 mmHg) by Maitre et al. [26]. As compared to COT, CPAP guaranteed higher SpO2 during and after the procedure, and lower numbers of patients required ventilatory assistance within the 6 h following the endoscopic procedure [26].

NIV during FOB
NIV via face mask was for the first time applied during FOB for BAL in 1996 [1]. In a cohort of immunosuppressed patients with suspected pneumonia and severe hypoxemia (PaO2/FiO2<100 mmHg), Antonelli et al. reported that NIV, applied 10 min before and discontinued 90 min after FOB, was well tolerated by all patients, improved gas exchange, and prevented the need for intubation [1].

Later on, the application of NIV via face mask was also evaluated in immunocompetent patients with hypoxic ARF of different severity. NIV provided optimal gas exchange during and after FOB [27–29], without causing hemodynamic impairments [27], and was also associated with a low incidence of minor complications [29], and with a small percentage of patients requiring intubation during the first 8 h after the procedure [28, 29].
At that time, facial masks were adapted with swivel connectors [28] or sealed ports [27] for the passage of the bronchoscope into the interface and patients’ airways. Nasal masks have been proposed as a valid alternative to facial masks for NIV during FOB [30]. In addition, new masks for NIV specifically designed for FOB were also tested [29–31]. Lastly, helmet NIV represents another feasible and safe alternative to NIV via mask during FOB for BAL in patients with hypoxemic ARF [32].

The use of NIV during FOB has been also extended to more complicated procedures, such as transbronchial lung biopsy [33] and interventional procedures, including balloon dilation, electrocautery and argon plasma coagulation [34]. In keeping with the above-mentioned studies, NIV guaranteed a stable oxygenation [33, 34] and good patients’ tolerance [33], whereas minor complications [34], as well as the number of patients requiring intubation after the procedure [33], were quite low. Similar findings have been also reported for patients with chronic [35] and acute-on-chronic [36, 37] respiratory failure.

The growing evidence in favor of both HFNC and NIV has yielded some studies comparing the two modalities in patients with mild-to-moderate hypoxemic ARF. Compared to HFNC, NIV improved oxygenation before, during and after FOB [38, 39], as well as decreased the number of desaturations <90% [39], without any difference in mortality or in the rate of patients requiring intubation and invasive mechanical ventilation [38, 39].

Quantitative synthesis of study findings

Figures 2 and 3 depict the quantitative synthesis of HFNC versus COT with respect to the lowest saturation and the episodes of desaturation during the FOB, respectively. Funnel plots for visual inspection of heterogeneity are included in the Additional file 1: Figures S1 and S2, respectively. In comparison with COT, HFNC significantly improves the lowest saturation (MD 7.04 [95%CI: 5.14 to 8.95]; p < 0.001; I² = 50%) and it significantly reduces the number of episodes of desaturation (RR 0.25 [95%CI: 0.14 to 0.42]; p < 0.001; I² = 0%).

In addition, Figs. 4 and 5 depict the quantitative synthesis of HFNC versus NIV with respect to the lowest saturation and the episodes of desaturation during the FOB, respectively. Funnel plots for visual inspection of heterogeneity are also included in the Additional file 1: Figures S3 and S4, respectively. As opposed to NIV, HFNC is characterized by a reduced lowest saturation (MD −2.63 [95%CI: −4.99 to −0.28]; p = 0.03; I² = 0%). On the opposite, HFNC and NIV do not differ with respect to the number of episodes of desaturation (RR 2.88 [95%CI: 0.88 to 9.44]; p = 0.08; I² = not applicable). Noteworthy, these data are reported only in the study by Simon et al. [38].
Discussion
Although several studies showed benefits from different oxygenation strategies during FOB, no clear guidelines are yet available in literature. Overall, the worst is the patient’s baseline lung function prior to the procedure, the highest is the oxygen requirement within the procedure and the risk of worsening ARF afterwards.
HFNC was shown to be safe in the majority of patients affected by mild-to-moderate ARF undergoing FOB for either diagnosis or treatment, and in those with lung transplant, while NIV ensured stable oxygenation when FOB was carried out for extended procedures or in patients with more severe ARF. However, information is still very scarce about the eventual better advantages of one strategy compared to another. All patients’ categories mentioned in the reviewed studies, as well as the oxygenation modalities which resulted more successful, have been summarized in Table 2. Generally speaking, by the pooled data analysis, HFNC outperforms COT with respect to oxygenation outcomes in patients with lower oxygen requirement, whereas data suggest the superiority of NIV in patients with more severe ARF, as compared to HFNC. Although the lack of sufficient evidence prevents the possibility to provide a clear or definitive recommendation on the use of an oxygenation strategy over another one, the oxygenation improvement during the procedure still remains an important safety issue for patients undergoing FOB. In addition, it potentially may improve major

| Study or Subgroup | HFNC | NIV | Mean Difference IV, Random, 95% CI |
|-------------------|------|-----|----------------------------------|
| Sakristichikoh 2019 | 92.2 | 94.6 | -2.40 [-5.42, 0.62] |
| Simon 2014 | 92 | 95 | -3.00 [-6.77, 0.77] |
| Total (95% CI) | 46 | 45 | -2.63 [-4.99, -0.28] |

Fig. 4 Quantitative synthesis of HFNC versus NIV with respect to the lowest saturation

| Study or Subgroup | HFNC | NIV | Mean Difference M–H, Random, 95% CI |
|-------------------|------|-----|----------------------------------|
| Sakristichikoh 2019 | 9 | 3 | 2.88 [0.88, 4.44] |
| Simon 2014 | 0 | 0 | Not estimable |
| Total (95% CI) | 46 | 45 | 2.88 [0.88, 4.44] |

Fig. 5 Quantitative synthesis of HFNC versus NIV with respect to the episodes of desaturation during the FOB

Table 2 The table summarizes the oxygen modalities that have been adopted according to the underlying patient’s lung disorder and FOB indications current literature
clinical outcomes (such as the need for hospital or ICU admission for post-procedural respiratory failure); however, such benefits require to be addressed.

In such a heterogeneous scenario of lung conditions, and with FOB implicated in a variety of diagnostic and therapeutic procedures, a score able to predict the occurrence of adverse events could support the clinician when deciding the best oxygenation modality. In order to develop such a score, a relevant scientific effort based on a multicenter research study would be useful.

The choice of oxygenation strategy may interfere with the route of access of the FOB. For example, during HFNC the presence of large bore nasal prongs prevents the possibility to use the nasal route, leading the physician to insert the FOB through the mouth. Noteworthy, the small positive expiratory airway pressure generated by HFNC would be significantly reduced during open mouth breathing, loosing theoretically its benefit on alveolar distending pressure and lung de-recruitment prevention [49]. However, we have recently demonstrated that in outpatients undergoing FOB with BAL, when compared to COT, HFNC prevents oxygenation worsening by avoiding end-expiratory loss of lung volume and preserves the same tidal volume with a lower diaphragm activation [18]. Therefore, based on our experience and recent data [18], we suggest the use of HFNC, rather than COT, in out-patients undergoing FOB with BAL.

On the opposite, some interfaces (helmet and face masks) for CPAP or NIV have been specifically designed to be used during FOB, which allow both oral and nasal route for bronchoscope insertion. For example, Korkmaz Ekren et al. have used a dedicated full-face mask with an interchangeable connector between the ventilator tubing and the mask that allows the insertion of the bronchoscope through a sealed-hole [29]. In another study by Heunks et al. [31], the investigators used a total face mask with a dedicated sealed hole below the connector between ventilator tubing and interface allowing the performance of the FOB through the mouth during NIV. However, air-leaks may occur around the interface or through the dedicated hole for FOB insertion, leading to patient-ventilator asynchronies which may be difficult to be managed [8, 55]. As a suggestion based on our experience and previous data [26], CPAP may be preferable over NIV for some reasons: first of all, CPAP is more user-friendly to be applied, as compared to NIV. In fact, the need of a simple flow generator, rather than a ventilator, makes CPAP easy to be applied. Moreover, although both CPAP and NIV guarantee the application of positive airway pressure throughout the whole respiratory cycle, the latter requires to adjust ventilator settings in order to improve the patient-ventilator synchrony during the inspiratory phase [8, 55].

The oxygenation strategy should also be chosen according to the procedure. Although some procedures (i.e. FOB with BAL) may be performed with an extensive topical anesthesia, others (i.e. EBUS) may require deeper sedation with different pharmacological strategies including both sedatives (i.e. midazolam, propofol or dexmedetomidine) and analgesics (i.e. remifentanil). However, it must be recognized that these drugs can modify the critical closing pressure of the upper airways, inducing their collapse [56, 57], and they can affect the breathing pattern and/or the respiratory drive. In particular, the deeper is the sedation, the higher is the modification [58, 59]. Therefore, in case of deep sedation, NIV (or even the placement of a laryngeal mask) may be required and preferred over other oxygenation strategies to ensure breathing and gas-exchange. A literature review and, eventually, trials focused on this topic are advisable.

Finally, in the era of the ongoing epidemic, a careful choice of oxygenation strategy should also be done in case of patients with suspected or confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. FOB is considered as aerosol generating procedure generating a significant number of droplets that can be contagious for other patients and the healthcare personnel [60]. Operators should firstly check the infection by SARS-CoV-2 through molecular test with naso-pharyngeal swabs; in case of positivity, full personal protective equipment (i.e. FFP-2 masks, gloves, goggles, face shields and gowns) are required. Furthermore, when exhaled air is released into the room, the dispersion of the virus may increase the risk of infection of other patients and the healthcare personnel [61]. It is well known that different interfaces are characterized by dissimilar air dispersion distances during their application [62, 63]. In principle, the use of a helmet for CPAP or NIV with a good seal around the neck is preferable, and, as abovementioned, the appropriate use of personal protective equipment is mandatory. In addition, simple practical measurements like reducing the number of assisting personnel and cough restriction with the administration of oropharyngeal lignocaine can minimize the contamination risk [60]. Of note, masks with vent holes should be avoided and a filter between the mask and the vent or PEEP valve is advisable to reduce viral transmission [61].

To our knowledge, this is the first review outlining the oxygenation strategies during FOB, and data are updated to the last available literature sources. Despite the consistent number of cited studies, the majority of them assessed the oxygenation effects on physiological, rather than major clinical outcomes. The quality of reviewed studies is also questionable, due to the small sample size and the high population heterogeneity preventing a further meta-analysis. Moreover, most of included studies
are single-centered. Finally, studies enroll patients which are not exclusively chronic or acute, but sometimes are mixed or not clear populations, preventing us to the possibility to separate the findings on different oxygenation strategies according to the clinical status of the patients. Hence, finding generalization is limited, as supported by weak evidence. Noteworthy, this review highlights the need for future research and robust data, in order to draw specific recommendations in a field where clinical practice nowadays is left to single-center experience, rather than scientific evidence.

**Conclusion**

In conclusion, the oxygenation strategy during FOB should be chosen according to the procedure, lung and heart function, oxygen requirement within the procedure and the risk of worsening ARF afterwards. In patients with mild-to-moderate oxygen requirement, HFNC would be preferable over COT, while the use of CPAP or NIV is encourageable in patients with more severe hypoxemia.

**Abbreviations**

ARF: Acute respiratory failure; BAL: Broncho-alveolar lavage; COT: Conventional oxygen therapy; CPAP: Continuous positive airway pressure; EBUS: Endobronchial ultrasound; ESM: Electronic supplemental material; FEV1: Forced expiratory volume in the first second; FiO2: Inspired oxygen fraction; FOB: Fiberoptic bronchoscopy; HFNC: High flow nasal cannula; NIV: Non-invasive ventilation; PaO2/FiO2: Arterial partial pressure to inspired oxygen fraction ratio; PEEP: Positive end-expiratory pressure; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; SpO2: Peripheral arterial oxyhemoglobin saturation.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12931-021-01846-1.

**Competing interests**

Dr. Navalesi's research laboratory has received equipment and grants from Draeger and Intersurgical S.p.A. He also received honoraria/speaking fees from Philips, Resmed, MSD and Novartis. Dr. Navalesi contributed to the development of the helmet Next, whose license for patent belongs to Intersurgical S.P.A. and receives royalties for that invention. Dr. Longhini and Dr. Navalesi contributed to the development of a new device (not discussed in the present study), whose patent is in progress (European Patent application number EP20170199831). The remaining authors have no conflict of interest to disclose.

**Author details**

1 Pulmonary Medicine Unit, Department of Health Sciences, "Magna Graecia" University, Catanzaro, Italy. 2 Anesthesia and Intensive Care Unit, Department of Medical and Surgical Sciences, "Mater Domini" University Hospital, "Magna Graecia" University, Viale Europa, 88100 Catanzaro, Italy. 3 Department of Emergency Medicine, Royal London Hospital, Barts Health NHS Trust, London, UK. 4 Anesthesia and General Intensive Care, "Maggiore Della Carità" University Hospital, Novara, Italy. 5 Department of Medicine-DIMED, Anesthesia and Intensive Care, Padua Hospital, University of Padua, Padua, Italy.

Received: 24 May 2021   Accepted: 18 September 2021

**Published online:** 25 September 2021
53. Cammarota G, Olivieri C, Costa R, Vaschetto R, Colombo D, Turucz E, et al. Noninvasive ventilation through a helmet in postextubation hypoxemic patients: physiologic comparison between neurally adjusted ventilatory assist and pressure support ventilation. Intensive Care Med. 2011;37(12):1943–50.

54. Longhini F, Pan C, Xie J, Cammarota G, Bruni A, Garofalo E, et al. New setting of neurally adjusted ventilatory assist for noninvasive ventilation by facial mask: a physiologic study. Crit Care. 2017;21(1):170.

55. Bruni A, Garofalo E, Pelaia C, Messina A, Cammarota G, Murabito P, et al. Patient-ventilator asynchrony in adult critically ill patients. Minerva Anestesiol. 2019;85(6):676–88.

56. Eastwood PR, Platt PR, Shepherd K, Maddison K, Hillman DR. collapsibility of the upper airway at different concentrations of propofol anesthesia. Anesthesiology. 2005;103(3):470–7.

57. Shteamer JW, Dedhia RC. Sedative choice in drug-induced sleep endoscopy: a neuropharmacology-based review. Laryngoscope. 2017;127(1):273–9.

58. Costa R, Navalesi P, Cammarota G, Longhini F, Spinazzola G, Cipriani F, et al. Remifentanil effects on respiratory drive and timing during pressure support ventilation and neurally adjusted ventilatory assist. Respir Physiol Neurobiol. 2017;244:10–6.

59. Vaschetto R, Cammarota G, Colombo D, Longhini F, Grossi F, Giovannelli A, et al. Effects of propofol on patient-ventilator synchrony and interaction during pressure support ventilation and neurally adjusted ventilatory assist. Crit Care Med. 2014;42(1):74–82.

60. Sampsonas F, Kakoulis L, Karampitsakos T, Papaioannou O, Katsaras M, Papachristodoulou E, et al. Bronchoscopy during the COVID-19 pandemic: effect on current practices and strategies to reduce procedure-associated transmission. Expert Rev Respir Med. 2021. https://doi.org/10.1080/17476348.2021.1913058.

61. Guan L, Zhou L, Zhang J, Peng W, Chen R. More awareness is needed for severe acute respiratory syndrome coronavirus 2019 transmission through exhaled air during non-invasive respiratory support: experience from China. Eur Respir J. 2020;55(3):2000352.

62. Hui DS, Chow BK, Lo T, Ng SS, Ko FW, Gin T, et al. Exhaled air dispersion during noninvasive ventilation via helmets and a total facemask. Chest. 2015;147(5):1336–43.

63. Hui DS, Chow BK, Lo T, Tsang OTY, Ko FW, Ng SS, et al. Exhaled air dispersion during high-flow nasal cannula therapy versus CPAP via different masks. Eur Respir J. 2019;53(4):1802339.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.